{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:13:19Z","timestamp":1792458799536,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":90,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Barth syndrome (BTHS) is a rare X-linked mitochondrial disorder characterized by cardiomyopathy, neutropenia, and skeletal myopathy. Elamipretide is a mitochondria-targeting peptide that stabilizes cardiolipin and improves mitochondrial function. While use of this treatment in infants with BTHS has been reported in the United States, no cases have been described outside the US or in older children.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We report the first case of a preschool-aged child with genetically confirmed BTHS and advanced heart failure, who was treated with elamipretide under a compassionate use program approved by the French Drug Administration (ANSM). At treatment initiation, this 5-year-old patient presented with severe left ventricular dysfunction (LVEF\u2009=\u200920%) and moderate-to-severe mitral regurgitation. He was dependent on gastrostomy feeding and had been listed for heart transplantation. Subcutaneous elamipretide (10\u00a0mg\/day) was initiated alongside maximal conventional heart failure therapy. Over six months, LVEF improved to 50%, mitral regurgitation decreased to mild, Ross class improved from IV to I, and substantial gains were observed in functional capacity, nutritional status, and health-related quality of life (HRQoL). The patient returned to full-time school and remained temporarily suspended from the transplant list. Treatment was generally well tolerated. One transient, non-serious episode of abdominal pain with moderate pancreatic enzyme elevation occurred, which resolved without treatment discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This case suggests that elamipretide may improve cardiac function, exercise tolerance, nutrition, and HRQoL in preschool-aged pediatric BTHS patients, potentially delaying the need for transplantation. Broader pediatric evaluation is warranted. Further strategies, such as youth-tailored hybrid cardiac rehabilitation programs, could complement pharmacological therapy and further optimize outcomes in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-026-04487-z","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T10:07:44Z","timestamp":1783418864000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Elamipretide in pediatric Barth syndrome: from heart failure to school return"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3649-0294","authenticated-orcid":false,"given":"Pascal","family":"Amedro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1025-7909","authenticated-orcid":false,"given":"Mathieu","family":"Andrianoely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4258-9204","authenticated-orcid":false,"given":"Pauline","family":"Gohier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Leroux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0231-4460","authenticated-orcid":false,"given":"Nathalie","family":"Aladjidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Lagorce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Daccord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Audie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Botte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7556-8081","authenticated-orcid":false,"given":"Karine","family":"Nubret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2390-3005","authenticated-orcid":false,"given":"Pascale","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Roche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Lamireau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candice","family":"Tetard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3457-5684","authenticated-orcid":false,"given":"Aurelien","family":"Trimouille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4073-323X","authenticated-orcid":false,"given":"Arielle","family":"Desir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Mesli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4485-146X","authenticated-orcid":false,"given":"Jean","family":"Donadieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7744-7028","authenticated-orcid":false,"given":"Julien","family":"Gotchac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"4487_CR1","doi-asserted-by":"crossref","unstructured":"Clarke SL, Bowron A, Gonzalez IL, Groves SJ, Newbury-Ecob R, Clayton N et al. Barth syndrome. Orphanet J Rare Dis. 2013;8.","DOI":"10.1186\/1750-1172-8-23"},{"key":"4487_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/jimd.12422","volume":"45","author":"C Taylor","year":"2022","unstructured":"Taylor C, Rao ES, Pierre G, Chronopoulou E, Hornby B, Heyman A, et al. Clinical presentation and natural history of Barth Syndrome: An overview. J Inher Metab Disea. 2022;45:7\u201316. https:\/\/doi.org\/10.1002\/jimd.12422.","journal-title":"J Inher Metab Disea"},{"key":"4487_CR3","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1750-1172-8-70","volume":"8","author":"C Rigaud","year":"2013","unstructured":"Rigaud C, Lebre A-S, Touraine R, Beaupain B, Ottolenghi C, Chabli A, et al. Natural history of Barth syndrome: a national cohort study of 22 patients. Orphanet J Rare Dis. 2013;8:70. https:\/\/doi.org\/10.1186\/1750-1172-8-70.","journal-title":"Orphanet J Rare Dis"},{"key":"4487_CR4","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jpeds.2019.09.074","volume":"217","author":"PC Miller","year":"2020","unstructured":"Miller PC, Ren M, Schlame M, Toth MJ, Phoon CKL. A Bayesian Analysis to Determine the Prevalence of Barth Syndrome in the Pediatric Population. J Pediatr. 2020;217:139\u201344. https:\/\/doi.org\/10.1016\/j.jpeds.2019.09.074.","journal-title":"J Pediatr"},{"key":"4487_CR5","doi-asserted-by":"publisher","first-page":"101005","DOI":"10.1016\/j.jbc.2021.101005","volume":"297","author":"AF Anzmann","year":"2021","unstructured":"Anzmann AF, Sniezek OL, Pado A, Busa V, Vaz FM, Kreimer SD, et al. Diverse mitochondrial abnormalities in a new cellular model of TAFFAZZIN deficiency are remediated by cardiolipin-interacting small molecules. J Biol Chem. 2021;297:101005. https:\/\/doi.org\/10.1016\/j.jbc.2021.101005.","journal-title":"J Biol Chem"},{"key":"4487_CR6","doi-asserted-by":"publisher","unstructured":"Sabbah HN, Gupta RC, Kohli S, Wang M, Hachem S, Zhang K. Chronic therapy with elamipretide (mtp-131), a novel mitochondria-targeting peptide, improves left ventricular and mitochondrial function in dogs with advanced heart failure. Circ Heart Fail. 2016;9. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.115.002206.","DOI":"10.1161\/CIRCHEARTFAILURE.115.002206"},{"key":"4487_CR7","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s10741-020-10031-3","volume":"26","author":"HN Sabbah","year":"2021","unstructured":"Sabbah HN. Barth syndrome cardiomyopathy: targeting the mitochondria with elamipretide. Heart Fail Rev. 2021;26:237\u201353. https:\/\/doi.org\/10.1007\/s10741-020-10031-3.","journal-title":"Heart Fail Rev"},{"key":"4487_CR8","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41436-020-01006-8","volume":"23","author":"W Reid Thompson","year":"2021","unstructured":"Reid Thompson W, Hornby B, Manuel R, Bradley E, Laux J, Carr J, et al. A phase 2\/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. Genet Sci. 2021;23:471\u20138. https:\/\/doi.org\/10.1038\/s41436-020-01006-8.","journal-title":"Genet Sci"},{"key":"4487_CR9","doi-asserted-by":"publisher","first-page":"101138","DOI":"10.1016\/j.gim.2024.101138","volume":"26","author":"WR Thompson","year":"2024","unstructured":"Thompson WR, Manuel R, Abbruscato A, Carr J, Campbell J, Hornby B, et al. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER. Genet Sci. 2024;26:101138. https:\/\/doi.org\/10.1016\/j.gim.2024.101138.","journal-title":"Genet Sci"},{"key":"4487_CR10","doi-asserted-by":"publisher","first-page":"ytaf030","DOI":"10.1093\/ehjcr\/ytaf030","volume":"9","author":"L Ortmann","year":"2025","unstructured":"Ortmann L, Velasco D, Cole J. L <>MonzoNuzziBrunoKad\u00edc V G F editors. 2025 Expanded-access use of elamipretide in a newborn with Barth syndrome: a case report. Eur Heart J - Case Rep 9 ytaf030 https:\/\/doi.org\/10.1093\/ehjcr\/ytaf030.","journal-title":"Eur Heart J - Case Rep"},{"key":"4487_CR11","doi-asserted-by":"publisher","first-page":"101859","DOI":"10.1016\/j.gimo.2024.101859","volume":"2","author":"AC Goldstein","year":"2024","unstructured":"Goldstein AC, Pantano C, Redko M, MacMullen LE, Maeda K, O\u2019Connor MJ. Expanded-access use of elamipretide in a critically ill patient with Barth syndrome. Genet Med Open. 2024;2:101859. https:\/\/doi.org\/10.1016\/j.gimo.2024.101859.","journal-title":"Genet Med Open"},{"key":"4487_CR12","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jpeds.2006.12.052","volume":"150","author":"R Geiger","year":"2007","unstructured":"Geiger R, Strasak A, Treml B, Gasser K, Kleinsasser A, Fischer V, et al. Six-minute walk test in children and adolescents. J Pediatr. 2007;150:395\u20139. https:\/\/doi.org\/10.1016\/j.jpeds.2006.12.052. 399.e1-2.","journal-title":"J Pediatr"},{"key":"4487_CR13","doi-asserted-by":"publisher","first-page":"8026","DOI":"10.3390\/ijerph17218026","volume":"17","author":"J G\u0105sior","year":"2020","unstructured":"G\u0105sior J, Paw\u0142owski M, Jele\u0144 P, Rameckers E, Williams C, Makuch R, et al. Test\u2013Retest Reliability of Handgrip Strength Measurement in Children and Preadolescents. IJERPH. 2020;17:8026. https:\/\/doi.org\/10.3390\/ijerph17218026.","journal-title":"IJERPH"},{"key":"4487_CR14","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1519\/JSC.0b013e3181ddb03d","volume":"24","author":"J Castro-Pi\u00f1ero","year":"2010","unstructured":"Castro-Pi\u00f1ero J, Ortega FB, Artero EG, Girela-Rej\u00f3n MJ, Mora J, Sj\u00f6str\u00f6m M, et al. Assessing Muscular Strength in Youth: Usefulness of Standing Long Jump as a General Index of Muscular Fitness. J Strength Conditioning Res. 2010;24:1810\u20137. https:\/\/doi.org\/10.1519\/JSC.0b013e3181ddb03d.","journal-title":"J Strength Conditioning Res"},{"key":"4487_CR15","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s40279-014-0281-8","volume":"45","author":"FB Ortega","year":"2015","unstructured":"Ortega FB, Cadenas-S\u00e1nchez C, S\u00e1nchez-Delgado G, Mora-Gonz\u00e1lez J, Mart\u00ednez-T\u00e9llez B, Artero EG, et al. Systematic Review and Proposal of a Field-Based Physical Fitness-Test Battery in Preschool Children: The PREFIT Battery. Sports Med. 2015;45:533\u201355. https:\/\/doi.org\/10.1007\/s40279-014-0281-8.","journal-title":"Sports Med"},{"key":"4487_CR16","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.jsams.2016.02.003","volume":"19","author":"C Cadenas-Sanchez","year":"2016","unstructured":"Cadenas-Sanchez C, Martinez-Tellez B, Sanchez-Delgado G, Mora-Gonzalez J, Castro-Pi\u00f1ero J, L\u00f6f M, et al. Assessing physical fitness in preschool children: Feasibility, reliability and practical recommendations for the PREFIT battery. J Sci Med Sport. 2016;19:910\u20135. https:\/\/doi.org\/10.1016\/j.jsams.2016.02.003.","journal-title":"J Sci Med Sport"},{"key":"4487_CR17","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s12966-015-0274-5","volume":"12","author":"AR Cooper","year":"2015","unstructured":"Cooper AR, Goodman A, Page AS, Sherar LB, Esliger DW, van Sluijs EMF, et al. Objectively measured physical activity and sedentary time in youth: the International children\u2019s accelerometry database (ICAD). Int J Behav Nutr Phys Act. 2015;12:113. https:\/\/doi.org\/10.1186\/s12966-015-0274-5.","journal-title":"Int J Behav Nutr Phys Act"},{"key":"4487_CR18","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1136\/bjsports-2020-102955","volume":"54","author":"FC Bull","year":"2020","unstructured":"Bull FC, Al-Ansari SS, Biddle S, Borodulin K, Buman MP, Cardon G, et al. World Health Organization 2020 guidelines on physical activity and sedentary behaviour. Br J Sports Med. 2020;54:1451\u201362. https:\/\/doi.org\/10.1136\/bjsports-2020-102955.","journal-title":"Br J Sports Med"},{"key":"4487_CR19","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1367\/1539-4409(2003)003<0329:TPAAPP>2.0.CO;2","volume":"3","author":"JW Varni","year":"2003","unstructured":"Varni JW, Burwinkle TM, Seid M, Skarr D. The PedsQLy* 4.0 as a Pediatric Population Health Measure: Feasibility, Reliability, and Validity. Ambul Pediatr. 2003;3:329\u201341.","journal-title":"Ambul Pediatr"},{"key":"4487_CR20","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1177\/1043454203262680","volume":"21","author":"SL Dyer","year":"2004","unstructured":"Dyer SL, Collins CT, Baghurst P, Saxon B, Meachan B. Insuflon Versus Subcutaneous Injection for Cytokine Administration in Children and Adolescents: A Randomized Crossover Study. J Pediatr Oncol Nurs. 2004;21:79\u201386. https:\/\/doi.org\/10.1177\/1043454203262680.","journal-title":"J Pediatr Oncol Nurs"},{"key":"4487_CR21","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/j.1399-5448.2008.00449.x","volume":"10","author":"P Burdick","year":"2009","unstructured":"Burdick P, Cooper S, Horner B, Cobry E, McFann K, Chase HP. Use of a subcutaneous injection port to improve glycemic control in children with type 1 diabetes. Pediatr Diabetes. 2009;10:116\u20139. https:\/\/doi.org\/10.1111\/j.1399-5448.2008.00449.x.","journal-title":"Pediatr Diabetes"},{"key":"4487_CR22","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1002\/jmd2.12244","volume":"62","author":"KL Bohnert","year":"2021","unstructured":"Bohnert KL, Ditzenberger G, Bittel AJ, de las Fuentes L, Corti M, Pacak CA, et al. Resistance exercise training with protein supplementation improves skeletal muscle strength and improves quality of life in late adolescents and young adults with Barth syndrome: A pilot study. JIMD Rep. 2021;62:74\u201384. https:\/\/doi.org\/10.1002\/jmd2.12244.","journal-title":"JIMD Rep"},{"key":"4487_CR23","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/8904_2018_102","volume":"41","author":"AJ Bittel","year":"2018","unstructured":"Bittel AJ, Bohnert KL, Reeds DN, Peterson LR, de las Fuentes L, Corti M, et al. Reduced Muscle Strength in Barth Syndrome May Be Improved by Resistance Exercise Training: A Pilot Study. JIMD Rep. 2018;41:63\u201372. https:\/\/doi.org\/10.1007\/8904_2018_102.","journal-title":"JIMD Rep"},{"key":"4487_CR24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/8904_2016_553","volume":"32","author":"WT Cade","year":"2017","unstructured":"Cade WT, Reeds DN, Peterson LR, Bohnert KL, Tinius RA, Benni PB, et al. Endurance Exercise Training in Young Adults with Barth Syndrome: A Pilot Study. JIMD Rep. 2017;32:15\u201324. https:\/\/doi.org\/10.1007\/8904_2016_553.","journal-title":"JIMD Rep"},{"key":"4487_CR25","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1093\/eurheartj\/ehae085","volume":"45","author":"P Amedro","year":"2024","unstructured":"Amedro P, Gavotto A, Huguet H, Souilla L, Huby A-C, Matecki S, et al. Early hybrid cardiac rehabilitation in congenital heart disease: the QUALIREHAB trial. Eur Heart J. 2024;45:1458\u201373. https:\/\/doi.org\/10.1093\/eurheartj\/ehae085.","journal-title":"Eur Heart J"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04487-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04487-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04487-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:02:42Z","timestamp":1791216162000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04487-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4487"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04487-z","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"assertion":[{"value":"3 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki. Compassionate use of elamipretide was approved by the French Drug Administration (ANSM) within the Rare Disease Program. Written informed consent for treatment and participation in the study was obtained from the patient\u2019s parents.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent for publication of this case report and the accompanying clinical images was obtained from the patient\u2019s parents.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests. The manufacturer of elamipretide was not involved in the preparation, review, or approval of this manuscript.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"340"}}